Opinion Split Over ICH Proposal To Limit Safety Data Collection
Some Feel ICH Guide Can Jeopardize Data Collection
Executive Summary
A draft international guideline that proposes limiting safety data collection in premarket and postmarket trials if the drug’s safety profile is sufficiently characterized has drawn a varied response from a range of stakeholders in the EU.
You may also be interested in...
ICH Guide On Selective Reporting Of Safety Data Faces Major Rewrite
The International Council for Harmonisation is making big changes to its E19 guideline that proposes taking a targeted approach to safety data collection in some late-stage clinical trials. The draft guideline, which is largely similar to the US guideline on this topic, drew varied comments from stakeholders, including those from the EU.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.